Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Treatment medicine capable of degrading high-polymer tumor and sustained-release medicine for normal cell protective agent

A technology for the treatment of normal cells and tumors, which can be used in anti-tumor drugs, drug delivery, drug combination, etc., and can solve the problems of unsatisfactory effects of pulsed chemotherapy

Inactive Publication Date: 2009-06-03
盛小禹
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition to this, the general medication in tumor treatment is mostly pulsed administration (such as intravenous chemotherapy), and the interval between two chemotherapy can make the patient recover properly, but unfortunately, tumor cells are also rejuvenated during this process, so pulse Chemotherapy is often less effective

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Hepatocellular carcinoma is difficult to detect in the early stage and the survival period in the late stage is only about three months. It is still difficult to make a major breakthrough in treatment. The formulation of the sustained-release implant consists of degradable polymer compound polylactic acid, chemotherapy drug oxalate platinum, gemcitabine (Genza) and hepatocellular carcinoma targeting drug Sorafenib (Nexavar), cell apoptosis inducer arsenic trioxide and release The blocking agent tristearin is composed of glyceryl stearate and so on. The drug granules are externally sprayed with the anti-tumor antibiotic Pingyangmycin. Pingyangmycin not only has a good therapeutic effect on liver cancer, but also has an antibacterial effect, which can further prevent bacterial infection during the surgical implantation process.

[0032] Weigh 5.4 g of L-polylactic acid with a molecular weight of 50,000 and dissolve it in 25 ml of dichloromethane, add 0.2 g of platinum oxa...

Embodiment 2

[0034] Non-small cell lung cancer accounts for 80% of the total number of lung cancers. Adding tumor targeting and vascular growth factor inhibitory drugs while using conventional chemotherapy drugs will achieve better therapeutic effects. The formulation of the sustained-release implant consists of degradable polymer compound polylactic acid / polyglycolic acid, chemotherapy drug paclitaxel, carboplatin, tumor targeting drug gefitinib (Iressa) and angiogenesis factor inhibitor drug lenalidomide And the release retardant tristearin glycerin etc. composition. The drug granules are externally sprayed with the anti-tumor antibiotic phylloxetine, which not only has a therapeutic effect on lung cancer, but also has an antibacterial effect, which can further prevent bacterial infection during the surgical implantation process.

[0035] Weigh 10 grams of PLGA with a molecular weight of 50,000 and a polylactic acid / polyglycolic acid ratio of 9:1, and dissolve it in 40 ml of tetrahydrofu...

Embodiment 3

[0037] Pancreatic cancer is commonly known as the king of cancers. It is often difficult to detect in the early stage and is not sensitive to chemotherapy, and it will bring great pain to patients in the late stage. The formulation of the sustained-release implant consists of degradable polymer compound polylactic acid / polyglycolic acid, chemotherapy drug Gemzet, oxalate platinum, molecular targeting drug Erlotinib (Tarceva), chemotherapy sensitizer R-Vera Composed of Pamil and release retardant tristearin. The drug granules are externally sprayed with the anti-tumor antibiotic neocarcinogen. Neocarcinogen not only has a therapeutic effect on pancreatic cancer, but also has an antibacterial effect, which can further prevent bacterial infection during surgical implantation.

[0038] Weigh 2.3 grams of PLGA with a molecular weight of 50,000 and a polylactic acid / polyglycolic acid ratio of 9:1, dissolve it in 20 ml of acetone, add 0.3 grams of erlotinib, 0.22 grams of platinum ox...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
lengthaaaaaaaaaa
diameteraaaaaaaaaa
Login to View More

Abstract

The invention discloses a treatment medicine capable of degrading high-polymer tumor and a sustained-release medicine for normal cell protective agent. The sustained-release medicine comprises one or more of the following sustained-release systems: (1) a tumor tissue and peripheral implanted medicine sustained-release system; (2) an absorbable nanometer medicine sustained-release system containing a lymphaden tracking medicine in lymph; (3) a nanometer medicine sustained-release system in blood or body fluid; (4) a nanometer medicine sustained-release system in a specific tissue, wherein, the specific tissue can be a liver, a spleen, a lung or marrow. The treatment medicine for tumor comprises one or more of chemotherapeutic medicine, chemotherapeutic sensitizer and tumor targeting medicine, and uses amifostine as the normal cell protective agent. The range of tumor treatment is applicable to any tumor through changing different treatment medicines. The invention is a novel medicine application platform, can be used by any new medicine besides the existing medicines, and plays a role in conquering cancer finally.

Description

technical field [0001] The invention relates to a medicine for treating tumors, in particular, the invention relates to a degradable macromolecule tumor treatment medicine and a normal cell protective agent slow-release medicine. Background technique [0002] At present, the dosage forms of the existing tumor chemotherapy drugs are mainly intravenous administration, followed by oral administration, and there are very few other administration methods. During intravenous chemotherapy, the drug is distributed throughout the body, so the drug concentration in the tumor tissue cannot be very high, but normal tissues and organs are greatly damaged by the chemotherapy drug in the blood. Oral chemotherapy will cause gastrointestinal damage and changes in drug efficacy due to the first-pass effect of the liver, and the drug concentration in tumor tissue may not be very high. Moreover, the drug concentration in the body of the above two drug administration methods is distributed in a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61K31/661A61P35/00
CPCA61K45/06A61K31/661A61K9/00A61K45/00A61K47/30A61P35/00A61P35/02A61K2300/00
Inventor 盛小禹
Owner 盛小禹
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com